Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rosetta and NYU form melanoma pact:

This article was originally published in Clinica

Executive Summary

Rosetta Genomics has joined up with the NYU Medical Center to develop a diagnostic test for melanoma, using Rosetta's microRNA technology. The partnership will involve the use of Rosetta's diagnostic engine to screen more than 700 microRNAs in order to identify a diagnostic signature for the disease. The collaborators hope to identify microRNAs that can be used as prognostic indicators for the overall survival of melanoma patients, and to predict the risk that the cancer will metastasise. Rehovot, Israel-based Rosetta already has a pact with US-based NYU to develop a line of early detection products for lung and mesothelioma cancers. The firm also hopes to launch three novel tests during 2008, one for cancer of unknown primary (CUP) and two for lung cancer.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts